SCHEMBL25215919

SCHEMBL25215919

Cc1ccc(S(=O)(=O)Oc2cc(OS(=O)(=O)c3ccc(C)cc3)c(C(=O)N3Cc4cccc([N+](=O)[O-])c4C3)c(OCC3CCCCC3)c2C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 4/20 0.38
MAPT P10636 4/20 0.36
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GAA P10253 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP19A1 P11511 2/20 0.34
AKR1C3 P42330 1/20 0.33
AKR1C1 Q04828 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
CD4 P01730 2/20 0.33
HTT P42858 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
FKBP1A P62942 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25212540 0.89 F2 (0.36) F2MEN1KMT2AGAACD4
SCHEMBL25217291 0.86 CYP19A1 (0.38) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL25600347 0.84 MAPT (0.34) F2MAPTALDH1A1KMT2AGAA
SCHEMBL30970492 0.81 AKR1C3 (0.34) F2MAPTALDH1A1MEN1KMT2A
SCHEMBL30970495 0.81 F2 (0.35) F2MAPTALDH1A1MEN1KMT2A
SCHEMBL25248403 0.78 HSP90AA1 (0.40) F2ALDH1A1CD4
SCHEMBL30368071 0.77 ENPP1 (0.41) F2ALDH1A1MEN1KMT2AGAA
SCHEMBL25669112 0.77 ENPP1 (0.41) F2ALDH1A1MEN1KMT2AGAA
SCHEMBL31281667 0.77 ENPP3 (0.40) F2ALDH1A1MEN1KMT2AGAA
SCHEMBL25214972 0.76 QRFPR (0.42) MAPTALDH1A1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425453-A1 ISOINDOLINES AS PMS2 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2024-12-26 US disclosed
EP-4441031-A1 ISOINDOLINES AS PMS2 INHIBITORS Neophore Limited (GB) 2024-10-09 EP disclosed
WO-2023094834-A1 ISOINDOLINES AS PMS2 INHIBITORS Neophore Limited (GB) 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425453-A1 ISOINDOLINES AS PMS2 INHIBITORS PMS2, MSH2, RECQL F2 477/4885MAPT 3789/4885ALDH1A1 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.